Personalized cell therapy market is estimated to witness high growth, owing to increasing disease burden and expanding therapeutic applications
Personalized cell therapy market is estimated to be valued at USD 14.12 Bn in 2024, exhibiting a CAGR of 24.4% over the forecast period 2024-2031. The market growth is driven by increasing prevalence of chronic diseases like cancer, cardiovascular diseases coupled with growing demand for customized treatment options. Furthermore, constant technological advancements in cell therapy development and expansion of therapeutic applications can also drive the market growth during forecast period.
Market Dynamics:
Global personalized cell therapy market growth is primarily driven by two major factors - increasing disease burden of chronic diseases and expanding therapeutic applications of cell therapies. Rising burden of chronic diseases like cancer and cardiovascular diseases globally boosts demand for more effective therapeutic solutions. Personalized cell therapies offer targeted treatment approaches with lower side effects and possibility of a cure. Therefore, these are increasingly being utilized for treating various cancer types, neurological disorders, cardiovascular diseases and others. Continuous research activities for developing new cell therapy products and exploring new therapeutic areas have broadened the application scope of these therapies. Several cell therapies are under clinical trials for conditions like diabetes, autoimmune disorders, that can drive the market growth in the future.
Major Drivers:
Increasing prevalence of chronic diseases boosts demand for personalized cell therapies
Global personalized cell therapy market growth is driven by rising prevalence of chronic and life-threatening diseases globally. Diseases such as cancer, cardiovascular diseases, diabetes and neurodegenerative disorders are becoming more widespread. According to the World Health Organization, non-communicable diseases caused 71% of all deaths globally in 2019. As these diseases have no cure currently and regular treatments have limitations, there is growing demand for advanced therapies like personalized cell therapies which offer the potential for regenerative treatments.
Advancements in cell therapy research and development
Continuous advancements in the research and development of cell-based therapies can drive the market growth. Scientists are making progress in understanding the mechanisms of various diseases and exploring the therapeutic potential of different cell types such as stem cells, T cells and dendritic cells. Many clinical trials are underway to evaluate the safety and efficacy of cell therapies in conditions, where existing alternatives are lacking. The number of approved cell therapy products and ongoing clinical trials have grown significantly in the past decade. This dynamic research environment can positively impact the market by bringing more personalized cell therapy candidates closer to commercialization and real-world use.
High costs of developing and delivering cell therapies
Extremely high costs associated with research, development and delivery of these advanced treatment solutions can hamper the market growth. Cell therapy products tend to have lengthy and expensive clinical trial and regulatory review processes due to complexity of the science and unproven risks. Manufacturing cell therapies also needs substantial investments in facilities, equipment and skilled labor to produce personalized medicines at a large scale. Health systems have to bear high one-time treatment costs for cell therapies, which are currently priced at hundreds of thousands to over a million USD per patient. This has limited accessibility for most patients globally.
Stringent regulatory pathways
Regulatory policies can also hamper the market growth as these are highly stringent for cell and gene therapy products due to critical safety concerns. Regulators want comprehensive evidence on quality, safety and efficacy before approving novel therapies. Navigating the regulatory pathways involves considerable time and cost burdens on developers. Any delays or rejection at the approval stage can significantly hamper a product's commercialization schedule and market penetration. Stricter post-approval monitoring is also mandated, which increases post-marketing responsibilities for companies. The rigid and evolving regulatory compliance requirements have slowed down the pace of bringing personalized cell therapies to patients.
Increasing investment from pharmaceutical companies offers new opportunities
Huge funding from pharmaceutical companies into cell therapy research and development can offer market growth opportunity. Major players are making large investments to enhance their cell therapy portfolios, either through acquisitions, partnerships, in-house initiatives or venture capital investments. For example, Novartis established its cell and gene therapy unit with plans to commit over US$ 700 million annually. Bristol-Myers Squibb spend US$ 150 million on a cell therapy research center. Such financial commitments from leading players signify growing confidence and open new avenues for clinical research.
Personalized therapy models
Applying personalized therapy approaches for diseases currently lacking effective treatment options can also offer growth opportunities. Diseases such as multiple sclerosis, Alzheimer's, Parkinson's and type 1 diabetes are aggressively being targeted with customized cell-based solutions. Any success in these areas could translate to sizable patient populations opting for such advanced personalized remedies over conventional alternatives. The advent of technology-driven personalized therapy models targeting specific patient characteristics offers hope to populations suffering from previously untreatable chronic conditions.
Link: https://www.coherentmarketinsights.com/market-insight/personalized-cell-therapy-market-204
Key Developments:
- On March 14, 2024, Bristol Myers Squibb, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed CAR T cell therapy, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including specific inhibitors
- In October 2023, Aurion Biotech, a clinical stage biotech company, initiated a phase 1/2 clinical trial for AURN001, a novel cell therapy targeting corneal edema caused by corneal endothelial dysfunction. This therapy combines Y-27632, a Rho kinase inhibitor, with allogenic human corneal endothelial cells (neltependocel).
- In June 2023, Vertex Pharmaceuticals Incorporated, a biopharmaceutical company, and Lonza announced a strategic collaboration to enhance manufacturing capabilities for Vertex's differentiated islet cell therapies aimed at producing insulin for individuals with type 1 diabetes. This collaboration focuses on advancing the VX-264 and VX-880 programs, both currently in clinical trials.
- In May 2023, Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, entered into a global collaboration and licensing agreement with Cellular Biomedicine Group Inc. (CBMG) to jointly develop, manufacture, and commercialize advanced CAR T-cell therapies for the treatment of B-cell malignancies
Key Players: Novartis AG, Gilead Sciences, Inc., Pfizer Inc., Amgen Inc., Bluebird Bio, Inc., Personalis, Inc., Adaptimmune Therapeutics PLC, BioNTech SE, Sangamo Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., CRISPR Therapeutics AG, Caribou Biosciences, Inc., Mustang Bio, Inc., Fate Therapeutics, Inc., Atara Biotherapeutics, Inc., Holostem Terapie Avanzate S.r.l.
